InnoCan Pharma (TSE:INNO)
:INNO
Top Page
InnoCan Pharma
(INNO)
Select Model
Select Model
Rating:51Neutral
Price Target:
C$6.50
▼(-13.33% Downside)
Action:ReiteratedDate:04/02/26
The score is driven primarily by mixed financials: a solid, low-leverage balance sheet and improved 2025 cash flow are offset by continued net losses and a cooling revenue trajectory. Technical indicators add downside pressure (below key long-term moving averages and negative MACD), while valuation is limited by negative earnings and no stated dividend yield.
Positive Factors
Conservative Balance Sheet
Very low leverage and solid positive equity provide financial resilience, lowering refinancing and solvency risk. A stronger capital base supports continued R&D and product development spending and preserves optionality for strategic moves over the next 2–6 months.
Negative Factors
Ongoing Net Losses
Persistent net losses limit retained-capital accumulation and increase reliance on external funding to sustain growth. Continued unprofitability compresses strategic flexibility and heightens execution risk if cash generation falters in coming quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative Balance Sheet
Very low leverage and solid positive equity provide financial resilience, lowering refinancing and solvency risk. A stronger capital base supports continued R&D and product development spending and preserves optionality for strategic moves over the next 2–6 months.
Read all positive factors
InnoCan Pharma (INNO) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$29.96M
Dividend YieldN/A
Average Volume (3M)920.00
Price to Earnings (P/E)―
Beta (1Y)-0.35
Revenue Growth-3.94%
EPS Growth-17.62%
CountryCA
Employees11
SectorConsumer Defensive
Sector Strength42
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.62
Shares Outstanding4,498,772
10 Day Avg. Volume392
30 Day Avg. Volume920
Financial Highlights & Ratios
PEG Ratio0.48
Price to Book (P/B)3.90
Price to Sales (P/S)0.82
P/FCF Ratio45.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
InnoCan Pharma Business Overview & Revenue Model
Company Description
InnoCan Pharma (INNO) is a biotechnology company focused on developing innovative therapeutic solutions leveraging cannabinoid-based technologies. The company operates primarily in the pharmaceutical and wellness sectors, with a core emphasis on c...
How the Company Makes Money
null...
InnoCan Pharma Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
74
Positive
Cash Flow
57
Neutral
| Breakdown | Dec 2025 | Mar 2025 | Mar 2024 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 26.61M | 29.44M | 13.66M | 2.56M | 196.00K |
| Gross Profit | 23.93M | 26.19M | 11.98M | 2.11M | 121.00K |
| EBITDA | 130.00K | 961.00K | -3.77M | -3.85M | -10.04M |
| Net Income | -1.12M | -1.83M | -4.70M | -3.89M | -10.06M |
Balance Sheet | |||||
| Total Assets | 10.52M | 9.26M | 6.94M | 6.98M | 12.57M |
| Cash, Cash Equivalents and Short-Term Investments | 6.69M | 5.01M | 3.88M | 4.95M | 11.05M |
| Total Debt | 930.00K | 10.00K | 33.00K | 34.00K | 1.00K |
| Total Liabilities | 2.29M | 2.24M | 2.55M | 751.00K | 3.56M |
| Stockholders Equity | 5.60M | 5.17M | 4.10M | 6.39M | 9.05M |
Cash Flow | |||||
| Free Cash Flow | 479.00K | -1.59M | -3.95M | -6.09M | -6.67M |
| Operating Cash Flow | 495.00K | -1.58M | -3.90M | -6.07M | -6.63M |
| Investing Cash Flow | -15.00K | 54.00K | -84.00K | -31.00K | -48.00K |
| Financing Cash Flow | 1.15M | 2.70M | 2.92M | 125.00K | 15.30M |
InnoCan Pharma Technical Analysis
Neutral
7.50
Price Trends
7.05
Negative
9.05
Negative
11.81
Negative
Market Momentum
-0.13
Negative
48.15
Neutral
48.58
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:INNO, the sentiment is Neutral. The current price of 7.5 is above the 20-day moving average (MA) of 6.47, above the 50-day MA of 7.05, and below the 200-day MA of 11.81, indicating a neutral trend. The MACD of -0.13 indicates Negative momentum. The RSI at 48.15 is Neutral, neither overbought nor oversold. The STOCH value of 48.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:INNO.
InnoCan Pharma Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
51 Neutral | C$29.96M | -19.43 | -71.80% | ― | -3.94% | -17.62% | |
50 Neutral | C$56.36M | -2.79 | -19.76% | ― | 26.91% | 81.01% | |
46 Neutral | C$18.85M | -5.08 | -68.32% | ― | 2.41% | 74.61% | |
45 Neutral | C$27.35M | -3.68 | -19.10% | ― | 18.06% | 34.58% | |
43 Neutral | C$24.11M | -7.74 | -256.01% | ― | ― | ― |
* Consumer Defensive Sector Average
TSE:INNO
InnoCan Pharma
6.66
-3.74
-35.96%
TSE:ATLE
Willow Biosciences Inc
0.16
0.11
226.53%
TSE:QNTM
Quantum Biopharma
5.60
-3.42
-37.92%
TSE:LABS
MediPharm Labs
0.07
-0.02
-23.53%
TSE:VM
Voyageur Pharmaceuticals
0.14
-0.04
-25.00%
TSE:AVCN
Avicanna
0.15
-0.09
-37.50%
InnoCan Pharma Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Innocan Pharma Secures Additional Insider Debenture Financing Ahead of Planned U.S. Offering
Positive
Mar 31, 2026
Innocan Pharma plans to issue an additional US$200,000 debenture to its largest shareholder, Tamar Innovest, following a prior US$450,000 debenture earlier in March, with both instruments carrying a 10% annual interest rate and secured under an ex...
Business Operations and StrategyDelistings and Listing ChangesPrivate Placements and Financing
Innocan Pharma Secures Insider Debenture Financing Ahead of Planned U.S. Listing
Positive
Mar 12, 2026
Innocan Pharma plans to issue a US$450,000 secured debenture to its largest shareholder, Tamar Innovest, bearing 10% annual interest and maturing in 12 months or upon completion of a planned U.S. public offering. Proceeds are earmarked for working...
Business Operations and StrategyProduct-Related Announcements
Innocan’s Long-Acting CBD Injection Shows Superiority to Placebo in Canine Pain Trial
Positive
Feb 9, 2026
Innocan Pharma reported that its liposomal synthetic cannabidiol (LPT-CBD) injection showed clinically meaningful pain relief versus placebo in a randomized, blinded crossover trial in dogs with naturally occurring osteoarthritis. The peer-reviewe...
Business Operations and StrategyDelistings and Listing ChangesPrivate Placements and Financing
Innocan Pharma Targets NYSE American Listing With Concurrent Offering
Positive
Jan 27, 2026
Innocan Pharma Corporation plans to list its common shares on the NYSE American around January 30, 2026, subject to final exchange approval, while simultaneously conducting a concurrent securities offering that will be detailed in future regulator...
Business Operations and StrategyDelistings and Listing ChangesPrivate Placements and Financing
Innocan Pharma Targets NYSE American Listing with Concurrent Securities Offering
Positive
Jan 2, 2026
Innocan Pharma Corporation plans to list its common shares on the NYSE American around January 7, 2026, pending final approval of its listing application and continued compliance with exchange requirements. In conjunction with the anticipated U.S....
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.